PT4
PT4 is a therapeutic agent against Cutaneous leishmaniasis (CL). PT4 is effective against both species of Leishmania, with IC50s of 125.18 and 233.18 μM for L. amazonensis and L. braziliensis, respectively. PT4 decreases of mitochondrial membrane potential and increases production of reactive oxygen species, which leads to parasite death. PT4 has a potent in vivo anti-inflammatory activity.
For research use only. We do not sell to patients.
- CAS No.: 1280738-47-7
- Formula: C18H14N4O2
- Molecular Weight:318.33
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Parasite Isoforms
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| J774.A1 | CC50 |
>500 μM
Compound: 58
|
Cytotoxicity against mouse J774.A1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against mouse J774.A1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 34171661] |
PT4 (0-1256.5 µM, 48 hours) can inhibit mammalian cells viability[1]. PT4 (314.1-19.6 μM, 48 hours) inhibits the growth of promastigote and amastigote of L. amazonensis and L. braziliensis promastigotes[1]. PT4 causes depolarization of the mitochondrial membrane of L. amazonensis and L. braziliensis promastigotes and increasing ROS in mitochondria[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Balb/c mice peritoneal exudate (mPEC), J774A.1 macrophages, Fibroblasts
-
Concentration:0-1256.5 µM
-
Incubation Time:48 hours
-
Result:Inhibited mPEC, J774A.1 and fibroblasts with CC50 value of 981.37 μM, 521.47 μM and 895.17 μM, respectively.
-
Cell Line:L. amazonensis, L. braziliensis promastigotes
-
Concentration:314.1-19.6 μM
-
Incubation Time:48 hours
-
Result:Inhibited promastigote of L. amazonensis and L. braziliensis promastigotes with IC50 value of 70.46 μM and 181.73 μM, respectively. Inhibited amastigote of them with IC50 value of 125.18 μM and 233.18 μM, respectively.
| Parameter | |
| HBA (≤10) | 4 |
| HBD (≤5) | 0 |
| LogP (≤5) | 2.23 |
| MW (≤500) g/mol | 318.33 |
| n-ROTB (≤10) | 4 |
| TPSA (A2) | 68.09 |
| BBB | Yes |
| GIA | High |
| P-GP substrate | No |
| Skin permeability (cm/s) | -6.85 |
| CYP450 2C9 inhibitor | Yes |
| CYP450 2D6 inhibitor | No |
| CYP450 2C19 inhibitor | Yes |
| CYP450 3A4 inhibitor | No |
| CYP450 1A2 inhibitor | Yes |
| Total Clearance (log ml/min/kg) | 0.117 |
| Renal OCT2 substrate | No |
| LD50 (mg/Kg) | 4700 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1280738-47-7
-
Molecular Weight 318.33
-
Formula C18H14N4O2
-
SMILES
O=C1N(CCN2N=NC(C3=CC=CC=C3)=C2)C(C4=C1C=CC=C4)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)